E-LIB Suche - Ergebnisse für: Chaput, N.

1

Clinical toxicology of immune checkpoint blockers:

Chaput, N.
Toxicology Letters. 350 (2021) - p. S52 , 2021

Link: https://doi.org/10.1016/..

2

PO-1227: A dose escalation phase 1 study of radiotherapy co..:

Boutros, C. ; Chaput, N. ; Lanoy, E....
Radiotherapy and Oncology. 152 (2020) - p. S646-S647 , 2020

Link: https://doi.org/10.1016/..

3

Baseline gut microbiota predicts clinical response and coli..:

Chaput, N. ; Lepage, P. ; Coutzac, C....
Annals of Oncology. 30 (2019) 12 - p. 2012 , 2019

Link: https://doi.org/10.1093/..

4

Circulating innate immune markers and outcomes in treatment..:

Charrier, M. ; Mezquita, L. ; Lueza, B....
European Journal of Cancer. 108 (2019) - p. 88-96 , 2019

Link: https://doi.org/10.1016/..

5

Immunotherapy in advanced gastric cancer, is it the future?:

Coutzac, C. ; Pernot, S. ; Chaput, N..
Critical Reviews in Oncology/Hematology. 133 (2019) - p. 25-32 , 2019

Link: https://doi.org/10.1016/..

6

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies..:

Marthey, L. ; Mateus, C. ; Mussini, C....
Journal of Crohn's and Colitis. 10 (2016) 4 - p. 395-401 , 2016

Link: https://doi.org/10.1093/..

7

Comparative Analysis of Sepax S-100, COBE 2991, and Manual ..:

Chiche-Lapierre, C.E. ; Tramalloni, D. ; Chaput, N..
Cytotherapy. 18 (2016) 6 - p. S47 , 2016

Link: https://doi.org/10.1016/..

8

Modes of action of ipilimumab and biomarkers of resistance ..:

Hannani, D. ; Vétizou, M. ; Enot, D....
Annales de Dermatologie et de Vénéréologie. 140 (2013) 12 - p. S627-S628 , 2013

Link: https://doi.org/10.1016/..

9

Dendritic cells and innate defense against tumor cells:

ULLRICH, E ; MENARD, C ; FLAMENT, C...
Cytokine & Growth Factor Reviews. 19 (2008) 1 - p. 79-92 , 2008

Link: https://doi.org/10.1016/..

10

Tumor-derived exosomes: a new source of tumor rejection ant..:

André, F ; Schartz, N.E.C ; Chaput, N...
Vaccine. 20 (2002) - p. A28-A31 , 2002

Link: https://doi.org/10.1016/..

11

Impact of intercurrent introduction of steroids on clinical..:

De Giglio A ; Mezquita L ; Auclin E...
info:eu-repo/semantics/altIdentifier/pmid/33007977. , 2020

Link: https://hdl.handle.net/1..

12

Circulating innate immune markers and outcomes in treatment..:

Charrier, M ; Mezquita, L ; Lueza, B...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ejca.2018.12.017. , 2019

Link: https://hal.science/hal-..

13

Circulating innate immune markers and outcomes in treatment..:

Charrier, M ; Mezquita, L ; Lueza, B...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ejca.2018.12.017. , 2019

Link: https://hal.archives-ouv..

14

Circulating innate immune markers and outcomes in treatment..:

Charrier, M ; Mezquita, L ; Lueza, B...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ejca.2018.12.017. , 2019

Link: https://hal.science/hal-..

15

Circulating innate immune markers and outcomes in treatment..:

Charrier, M ; Mezquita, L ; Lueza, B...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ejca.2018.12.017. , 2019

Link: https://hal.science/hal-..